Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 5Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 3Other hematologic neoplasm 2Gynecologic 2Tumor-Agnostic 1Thoracic 1Plasma cell 1Genitourinary 1CNS 1Breast 1

Conditions

Smoldering Multiple Myeloma 1Multiple Myeloma 1

Interventions

Dexamethasone 98daratumumab 57Lenalidomide 53Bortezomib 38pomalidomide 37Cyclophosphamide 37carfilzomib 25Calcium Dobesilate 25fludarabine 22talquetamab 19iberdomide 18isatuximab 17Specimen Handling 17Magnetic Resonance Spectroscopy 17Biopsy 15selinexor 13dexamethasone acetate 12belantamab mafodotin 12Melphalan 12dexamethasone 21-phosphate 11auricularum 10venetoclax 8fludarabine phosphate 7elotuzumab 7X-Rays 6tocilizumab 5Blood Specimen Collection 5ruxolitinib 4ixazomib 4Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Behavior Therapy × Plasma cell × Clear all
NCT05312255 2025-12-01

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

Roswell Park Cancer Institute

Phase NA Recruiting
175 enrolled
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡